Regeneron Pharmaceuticals (REGN) is back in focus after three pipeline updates in quick succession, including early Lynozyfic data in systemic AL amyloidosis, an accelerated EMA review for Otarmeni, and a large research collaboration with Parabilis Medicines.

Despite a series of fresh pipeline and partnership announcements, Regeneron’s share price is down 15% over the past month and 19% over the past quarter, while the 1 year total shareholder return is 6%. This suggests that long term holders have fared better than recent buyers.

If these biotech updates have your attention, it can be useful to see what else is happening in healthcare related AI, especially companies using data and automation to reshape drug discovery, diagnostics, or care delivery through 34 healthcare AI stocks

With the stock down double digits in recent months despite fresh trial wins, an accelerated gene therapy review and a multi billion dollar research deal, is Regeneron now trading at a discount, or is the market already pricing in future growth?

Most Popular Narrative: 27% Undervalued

Regeneron’s most followed narrative points to a fair value of $875.31 against a last close of $638.88, so the story hinges on how durable its growth engines really are.

Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.

Curious what sits behind that projected upside in revenue, margins, and future earnings multiples? The narrative leans on a specific growth path, clear profitability targets, and tighter analyst agreement than you might expect at this price.

Result: Fair Value of $875.31 (UNDERVALUED)

However, there are still clear pressure points, including ongoing EYLEA competition and pricing risk, as well as the chance that heavy R&D spend does not translate into expected blockbuster launches.

Next Steps

Given the mix of optimism and open questions, it makes sense to move quickly, check the facts for yourself, and weigh the upside and downside. Start by reviewing the 4 key rewards

Ready to find your next opportunity?

If Regeneron has sharpened your thinking, do not stop here, use the Simply Wall St Screener now to spot fresh stock ideas before others catch on.

• Target resilient income potential by scanning companies that look like genuine 10 dividend fortresses for steadier cash returns.
• Hunt for value by zeroing in on screener containing 21 high quality undiscovered gems that the broader market may not be focused on yet.
• Dial down risk by focusing on 68 resilient stocks with low risk scores that combine financial strength with more measured volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.